

Recommendations from York and Scarborough Medicines Commissioning Committee March 2015

Drug name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact
Rituximab for IV infusion (Mabthera®)	Autoimmune haemolytic anaemia (AIHA)	Approved	A 2 nd line option for the treatment of warm AIHA in adults with relapsing disease/refractory to corticosteroids. Rituximab is recommended as a 1 st line in cold AIHA. Specialist prescribing only.	Red	Unlikely to change.
Ibandronic acid 1mg/ml injection (Bonviva®)	Treatment of osteoporosis	Approved	Confirmation of RAG status.	Red	No impact on primary care budget.
Teriparatide 250mcg/ml injection (Forsteo®)	Treatment of osteoporosis	Approved	Confirmation of RAG status.	Red	No impact on primary care budget. PbR excluded.
Strontium sachets (Protelos®)	Treatment of osteoporosis	Approved	Revision to RAG status.	Amber – specialist initiation	No significant change to current usage expected.
Insulin aspart (Novarapid®) PumpCart cartridges 1.6mL	Type 1 diabetes	Approved	Continuous subcutaneous administration of insulin in the Accu-Chek Insight insulin pump.	Amber – specialist initiation	The overall cost of the insulin pump with this new cartridge offers better value. Four year insulin pump costs are £6,386.65 with this prefilled cartridge versus £7,109.53 for use of vials.

Additional items:

Vale of York CCG medal ranking – Calcium and vitamin D supplements

Vale of York CCG medal ranking - Bisphosphonates and other drugs affecting bone metabolism

NICE Technology Appraisals

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262). <http://www.nice.org.uk/guidance/ta329>

This technology has the potential for significant cost impact for CCGs, NICE costing template is included here to provide indicative costs.

<http://www.nice.org.uk/guidance/ta329/resources/ta329-infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-including-a-review-of-ta140-and-ta262-costing-stateme>